BCL2 and B-cell chronic lymphocytic leukemia: Current trials suggest the most potent therapeutic regimens for CLL will likely involve combinations of ibrutinib and the Bcl‐2 antagonist venetoclax.32 Venetoclax is limited by the presence of microenvironmental signals that up‐regulate Bcl‐2 family members it does not target.